- Boston University (B.A., 2001)
- Long Island University (M.S. Edu., 2004)
- Hofstra School of Law magna cum laude (J.D., 2008)
- New York State Bar
Elizabeth A. Brehm is an associate based in our New York office who concentrates on antitrust and securities litigation.Ms. Brehm joined the firm in 2011. Prior to her time at KM, Ms. Brehm practiced as an attorney in the New York office of Winston & Strawn LLP.
Some of Ms. Brehm’s relevant antitrust work includes:
- Representation of indirect purchasers in In re Cathode Ray Tube (CRT) Antitrust Litigation, a price fixing antitrust case alleging that defendant entities conspired to control prices of television and monitor components.
- Lead counsel for consumer classes in connection with antitrust proceedings against Microsoft in the United States and consulting and advisory counsel to Canadian lead counsel in Canada. These litigations have resulted in settlements totaling over $1 billion for consumers in Canada, Florida, New York, Tennessee, West Virginia and Minnesota, where the litigation proceeded to trial.
- Co-lead counsel on behalf of a proposed class of purchasers of iron pipe fittings for water projects in In re Ductile Iron Pipe Fittings Antitrust Litigation. Class representatives in this action include Wayne County, Michigan. This case settled for more than $17.3 million.
- Special fiduciary representation for the exchange-based class in In re Foreign Exchange Benchmark Rates Antitrust Litigation for a putative class of participants who traded futures and options in the FX market. The case has already resulted in partial settlements of more than $2.3 billion.
- Representation of the exchange-based class in In re LIBOR-Based Financial Instruments Antitrust Litigation, an antitrust case alleging that defendant banks colluded to misreport and manipulate LIBOR. This litigation has already resulted in a partial settlement of over $180 million.
- Court appointed Discovery Committee Co-Chair in In re Effexor XR Antitrust Litigation for a putative class of direct purchasers of brand name and generic equivalents of extended release venlafaxine hydrochloride capsules against drug manufacturers. Among the claims, Defendants are alleged to have delayed market entry of generic versions and entered into reverse payment settlements.
Some of Ms. Brehm’s other relevant work includes:
- Representation of a whistleblower in a qui tam action, State of New York v. Covanta Hempstead Company, alleging that a waste-energy company used improper ash disposal techniques, violative of environmental law.
- Representation in an individual lawsuit against Morgan Stanley pertaining to four fraudulent collateralized debt obligations. Plaintiff alleges that Morgan Stanley represented that independent collateral managers would select safe, high-quality reference entities to be included in the collateralized debt obligations’ underlying portfolios, but that in reality, Morgan Stanley controlled portfolio selection and chose high-risk collateral, while actively shorting that same collateral in order to enrich itself at its client's expense.
During her time at Winston & Strawn, Ms. Brehm focused on products liability litigation, including Estate of Bobby Hill v. U.S. Smokeless Tobacco Co., a wrongful death products liability lawsuit brought by the family of Bobby Hill against Altria Group, which had recently acquired U.S. Smokeless Tobacco Co. The lawsuit asserted that U.S. Smokeless Tobacco manufactured and sold smokeless tobacco that Bobby Hill began using when he was 13 years-old and that this led to the death of Mr. Hill at age 42 from tongue cancer. The case settled prior to trial.